WO2002046467A3 - Gene expression profiling of primary breast carcinomas using arrays of candidate genes - Google Patents

Gene expression profiling of primary breast carcinomas using arrays of candidate genes Download PDF

Info

Publication number
WO2002046467A3
WO2002046467A3 PCT/IB2001/002811 IB0102811W WO0246467A3 WO 2002046467 A3 WO2002046467 A3 WO 2002046467A3 IB 0102811 W IB0102811 W IB 0102811W WO 0246467 A3 WO0246467 A3 WO 0246467A3
Authority
WO
WIPO (PCT)
Prior art keywords
arrays
gene expression
expression profiling
candidate genes
primary breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/002811
Other languages
French (fr)
Other versions
WO2002046467A2 (en
Inventor
Francois Bertucci
Remi Houlgatte
Daniel Birnbaum
Catherine Nguyen
Patrice Viens
Vincent Fert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Qiagen Marseille SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Ipsogen SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Ipsogen SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to JP2002548184A priority Critical patent/JP2004537261A/en
Priority to CA002430981A priority patent/CA2430981A1/en
Priority to EP01985452A priority patent/EP1353947A2/en
Priority to AU2002234799A priority patent/AU2002234799A1/en
Publication of WO2002046467A2 publication Critical patent/WO2002046467A2/en
Anticipated expiration legal-status Critical
Publication of WO2002046467A3 publication Critical patent/WO2002046467A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to a polynucleotide library useful in the molecular characterization of a carcinoma, the library including a pool of polynucleotide sequences of subsequences thereof wherein the sequences of subsequences are overpressed in tumor cells, further wherein the sequences of subsequences correspond substantially to any of the polynucleotide sequences set forth in any of SEQ ID NOS: 1- 468 or the complement thereof. The invention relates also to polynucleotides arrays useful to differentiate tumor cells from normal cells comprising combinations of selected immobilized polynucleotide sequences sets.
PCT/IB2001/002811 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes Ceased WO2002046467A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002548184A JP2004537261A (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast cancer using an array of candidate genes
CA002430981A CA2430981A1 (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes
EP01985452A EP1353947A2 (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002234799A AU2002234799A1 (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25409000P 2000-12-08 2000-12-08
US60/254,090 2000-12-08
US10/007,926 2001-12-07
US10/007,926 US20030143539A1 (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Publications (2)

Publication Number Publication Date
WO2002046467A2 WO2002046467A2 (en) 2002-06-13
WO2002046467A3 true WO2002046467A3 (en) 2003-08-28

Family

ID=26677525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002811 Ceased WO2002046467A2 (en) 2000-12-08 2001-12-07 Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Country Status (6)

Country Link
US (3) US20030143539A1 (en)
EP (1) EP1353947A2 (en)
JP (2) JP2004537261A (en)
AU (1) AU2002234799A1 (en)
CA (1) CA2430981A1 (en)
WO (1) WO2002046467A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US6596643B2 (en) 2001-05-07 2003-07-22 Applied Materials, Inc. CVD TiSiN barrier for copper integration
WO2002099421A2 (en) * 2001-05-18 2002-12-12 Thomas Jefferson University Specific microarrays for breast cancer screening
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
DE10229391A1 (en) * 2002-06-29 2004-01-29 Forschungszentrum Karlsruhe Gmbh Biochip, useful for identifying metastatizing tumors and assessing metastatic potential, carries cDNA copies of genes with metastasis-specific expression and of control genes
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
AU2012206980B2 (en) * 2003-01-15 2015-02-05 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
US20040229225A1 (en) * 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2609234T3 (en) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction of the probability of cancer recurrence
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1522594A3 (en) * 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
EP1538218A1 (en) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for inflammatory diseases
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
JP2005270093A (en) * 2004-02-24 2005-10-06 Nippon Medical School Genes involved in predicting postoperative prognosis of breast cancer
WO2005080570A1 (en) 2004-02-24 2005-09-01 Mitsubishi Rayon Co., Ltd. Gene relating to estimation of postoperative prognosis for breast cancer
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20060063184A1 (en) * 2004-09-09 2006-03-23 Felix Carolyn A Compositions and methods for the detection of DNA topoisomerase II complexes with DNA
EP1815014B1 (en) 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (en) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド Predicting response to chemotherapy using gene expression markers
US20070072175A1 (en) * 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
TW200729050A (en) 2005-09-22 2007-08-01 China Synthetic Rubber Corp Gene expression profiling for identification of prognostic subclasses in nasopharyngeal carcinomas
WO2007141595A2 (en) * 2005-11-10 2007-12-13 Aurelium Biopharma Inc. Method of diagnosing breast cancer using protein markers
EP1989230B1 (en) 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same
EP2338898A1 (en) 2006-03-09 2011-06-29 The Board of Regents of the University of Texas System Compositions and methods related to profiling a plurality of cell lines based on peptide binding
EP2142670A1 (en) * 2007-04-05 2010-01-13 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
NZ582619A (en) 2007-08-03 2012-08-31 Genentech Inc Humanized anti-fgf19 antagonists and methods using same
EP2373809A1 (en) * 2008-12-10 2011-10-12 Ipsogen Methods for identifying erbb2 alteration in tumors
WO2010088498A1 (en) * 2009-01-30 2010-08-05 Bayer Healthcare Llc Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
US9575115B2 (en) 2012-10-11 2017-02-21 Globalfoundries Inc. Methodology of grading reliability and performance of chips across wafer
US9169509B2 (en) 2013-01-15 2015-10-27 Board Of Regents, The University Of Texas System Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity
AU2016238253B2 (en) 2015-03-25 2022-06-16 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
CN110050075B (en) 2016-10-27 2024-04-02 通用医疗公司 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BERTUCCI F ET AL: "EXPRESSION SCANNING OF AN ARRAY OF GROWTH CONTROL GENES IN HUMAN TUMOR CELL LINES", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 18, no. 26, 1999, pages 3905 - 3912, XP000979482, ISSN: 0950-9232 *
BERTUCCI FRANÇOIS ET AL: "Gene expression profiles of poor-prognosis primary breast cancer correlate with survival.", HUMAN MOLECULAR GENETICS. ENGLAND 15 APR 2002, vol. 11, no. 8, 15 April 2002 (2002-04-15), pages 863 - 872, XP001146244, ISSN: 0964-6906 *
BREAST CANCER RESEARCH AND TREATMENT. NETHERLANDS JUL 1997, vol. 44, no. 3, July 1997 (1997-07-01), pages 243 - 253, ISSN: 0167-6806 *
CAFFO O ET AL: "Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES SEP 1996, vol. 2, no. 9, September 1996 (1996-09-01), pages 1591 - 1599, XP001121315, ISSN: 1078-0432 *
CAO L. ET AL.: "Human gastric adenocarcinoma cathepsin B: isolation and sequencing of full-length cDNAs and polymorphism of the gene", GENE, vol. 139, no. 2, 1994, pages 163 - 169 *
DATABASE EBI [online] 20 May 1993 (1993-05-20), CAO L. ET AL., XP002235958, Database accession no. L16510 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 1997 (1997-07-01), SHAW-BRUHA C M ET AL: "Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing.", XP002235792, Database accession no. NLM9266104 *
FAIRCHILD C R ET AL: "ISOLATION OF AMPLIFIED AND OVEREXPRESSED DNA SEQUENCES FROM ADRIAMYCIN-RESISTANT HUMAN BREAST CANCER CELLS", CANCER RESEARCH, vol. 47, no. 19, 1987, pages 5141 - 5148, XP009006931, ISSN: 0008-5472 *
GRAHAM J D ET AL: "Regulation of the expression and activity by progestins of a member of the SOX gene family of transcriptional modulators.", JOURNAL OF MOLECULAR ENDOCRINOLOGY. ENGLAND JUN 1999, vol. 22, no. 3, June 1999 (1999-06-01), pages 295 - 304, XP000995364, ISSN: 0952-5041 *
HOCH R V ET AL: "GATA-3 is expressed in association with estrogen receptor in breast cancer.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 20 APR 1999, vol. 84, no. 2, 20 April 1999 (1999-04-20), pages 122 - 128, XP001146467, ISSN: 0020-7136 *
MAGUIRE T M ET AL: "High levels of cathepsin B predict poor outcome in patients with breast cancer.", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 13, no. 3, July 1998 (1998-07-01), pages 139 - 144, XP001118861, ISSN: 0393-6155 *
MATHOULIN-PORTIER M P ET AL: "Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.", ONCOLOGY REPORTS. GREECE 2000 MAY-JUN, vol. 7, no. 3, May 2000 (2000-05-01), pages 675 - 680, XP009007614, ISSN: 1021-335X *
PENAULT-LLORCA F ET AL: "Expression of FGF and FGF receptor genes in human breast cancer.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 10 APR 1995, vol. 61, no. 2, 10 April 1995 (1995-04-10), pages 170 - 176, XP009007615, ISSN: 0020-7136 *
PEROU C M ET AL: "Molecular portraits of human breast tumours.", NATURE. ENGLAND 17 AUG 2000, vol. 406, no. 6797, 17 August 2000 (2000-08-17), pages 747 - 752, XP002235791, ISSN: 0028-0836 *
VARGAS-ROIG L M ET AL: "c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 20 APR 1999, vol. 84, no. 2, 20 April 1999 (1999-04-20), pages 129 - 134, XP002235684, ISSN: 0020-7136 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
WO2002046467A2 (en) 2002-06-13
EP1353947A2 (en) 2003-10-22
US20130079234A1 (en) 2013-03-28
JP2008178411A (en) 2008-08-07
CA2430981A1 (en) 2002-06-13
AU2002234799A1 (en) 2002-06-18
JP2004537261A (en) 2004-12-16
US20110086765A1 (en) 2011-04-14
US20030143539A1 (en) 2003-07-31
JP4388983B2 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
WO2002046467A3 (en) Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2009039390A3 (en) The development of glycobiology-based therapeutics for the treatment of brain tumors
WO1999034004A3 (en) Metastatic breast and colon cancer regulated genes
EP1953229A3 (en) Metastatic breast and colon cancer regulated genes
WO2006110264A3 (en) Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
MXPA04004704A (en) Antimicrobial polypeptides from pseudoplectania nigrella.
WO2002044331A3 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2000040758A3 (en) Enhanced sequencing by hybridization using pools of probes
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
WO2003016565A3 (en) Dna sequence analysis
ATE528397T1 (en) GENE OVEREXPRESSED IN CANCER
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
DE69840333D1 (en) 2-M TRANSITION OF THE CELL CYCLE
WO2002010436A3 (en) Prognostic classification of breast cancer
JP2006518186A5 (en)
ZA200007270B (en) Novel Nucleotide sequences coding for the zwa2 gene.
WO2001023426A3 (en) Hypoxia-related human genes, proteins, and uses thereof
WO2001031029A3 (en) Human sphingosine kinase gene
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
Rochlitz et al. Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma
CO5280153A1 (en) ANTIGEN ASSOCIATED WITH TUMORS (R11)
NO20015526L (en) Polynucleotides and polypeptides encoded by these, distantly homologous to heparanase
MX9805299A (en) Novel polynucleotides panc1a and panc1b associated with pancreatic cancer.
JP2006501465A5 (en)
EP0811696A3 (en) Method to obtain nucleotide sequence using randomly primed amplification

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002548184

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001985452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2430981

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001985452

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642